Axsome Therapeutics, Inc. /
Baergic Bio, Inc.
Axsome Therapeutics to acquire Baergic Bio in subsidiary purchase
Source for the buyer and target: AVENUE THERAPEUTICS, INC.
For the buyer and target.
“Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (“Baergic”), today announced that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome”), including the global rights to BAER-101 (also known as AZD7325), a novel oral GABA A α2,3 subtype-selective receptor positive allosteric modulator (PAM).”
Published 12 Nov 2025
Open the sourceWhat happened
Axsome Therapeutics, Inc. agreed to acquire Baergic Bio, Inc., a subsidiary of Avenue Therapeutics, Inc. The transaction includes Baergic’s equity interests and worldwide rights to BAER-101, which Axsome will refer to as AXS-17. [01]
Baergic shareholders are eligible for an upfront payment of $0.3 million, potential development, regulatory and sales milestones, and royalties on potential global net sales. Avenue expects to receive approximately 74% of future payments and royalties. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Axsome Therapeutics to acquire Baergic Bio in subsidiary purchase
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly